New Data Presented at European Society for Medical Oncology Meeting Demonstrate Antitumor Activity with IONIS-STAT3-2.5 Rx in Combination with Imfinzi

29% Objective Response Rate and 57% Disease Control Rate in Combination with Immune Checkpoint Inhibitor Treatment in Patients with Head and Neck Cancer Four Complete Responses and Four Partial Responses Observed in 28-patient Study CARLSBAD, Calif., Sept. 11, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today reported that new data from the clinical program for IONIS-STAT3-2.5Rx (AZD9150) were presented at the 2017 European Society for Medical Oncology (ESMO) Annual Congress. The presentation included clinical and safety results from the Phase 1b/2 study evaluating the activity of IONIS-STAT3-2.5Rx in combination with Imfinzi (durvalumab), AstraZeneca's programmed death ligand (PD-L1) blocking antibody, in patients with advanced solid tumors and recurrent metastatic head and neck cancer. In the study, the combination treatment resulted in encouraging antitumor activity with a safety and tolerability profile supportive of continued development.

The release as fetched from its publisher. ionis.com ↗